Clinical Report: Efficacy of SBRT and Tislelizumab in Advanced NSCLC

Overview

This pilot case series explores the efficacy and safety of sequential stereotactic body radiotherapy (SBRT) and tislelizumab following platinum-doublet chemotherapy in patients with advanced non-squamous non-small cell lung cancer (NSCLC). Preliminary findings report a 1-year progression-free survival rate of 25% and a median overall survival of 26.89 months.

Background

Lung cancer remains the leading cause of cancer-related mortality globally, particularly in advanced stages where treatment options are limited. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases, and patients without actionable driver mutations face significant therapeutic challenges. This study investigates a treatment approach combining SBRT and immunotherapy.

Data Highlights

Key Findings

• The 1-year progression-free survival (PFS) rate was 25%.
• Median overall survival (OS) was 26.89 months.
• Best overall response rate (BOR) was 87.5%, with 7 patients achieving partial response.
• All patients experienced treatment-related adverse events (TRAEs), with 62.5% having grade ≥3 TRAEs.
• The study population consisted of patients with unresectable stage IIIB/C–IV NSCLC lacking actionable driver mutations.
• Individualized SBRT regimens varied in dose and fractionation from 3–10 Gy/fx.

Clinical Implications

The findings indicate that sequential SBRT and tislelizumab were evaluated in patients with advanced NSCLC. Further investigation in larger, controlled trials is necessary.

Conclusion

This pilot case series provides preliminary insights into the combination of SBRT with tislelizumab in advanced NSCLC, but further research is required.

Related Resources & Content

1. Heinzerling et al., The Lancet Oncology, 2024 -- Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally Advanced NSCLC
2. Heinzerling et al., The Lancet Oncology, 2024 -- Primary Lung Tumor SBRT Followed by Mediastinal Chemoradiotherapy in Locally Advanced NSCLC
3. Perioperative Tislelizumab Plus Chemotherapy in Resectable NSCLC, ASCO Post, 2024
4. ASCO Living Guideline, Version 2024.3 -- Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations
5. ASTRO/ESTRO Clinical Practice Guideline -- Treatment of Oligometastatic Non-Small Cell Lung Cancer
6. Frontiers in Oncology — Efficacy and safety of deep hyperthermia combined with tislelizumab and chemotherapy in the treatment of advanced squamous non-small-cell lung cancer: a single-center retrospective study
7. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3 | Journal of Clinical Oncology
8. Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline - PubMed
9. Radiotherapy to augment pembrolizumab responses and outcomes in metastatic non-small cell lung cancer: Pooled analysis of two randomized trials. | Journal of Clinical Oncology